Translate:
Baker McKenzie advised CureVac AG on a strategic collaboration agreement with GlaxoSmithKline (GSK) for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.

Advancing mRNA-based vaccine and treatment technologies is expected to play a role in further improving response against future pandemics. The companies will combine their mRNA expertise on development op-portunities across a range of infectious disease pathogens, selected with the potential to best leverage the advantages of this platform technology, while addressing significant unmet medical need and economic bur-den.

CureVac will be eligible to receive development and regulatory milestone payments of up to EUR 320 million, commercial milestone payments of up to EUR 380 million and tiered royalties on product sales. In addition, GSK will make an upfront cash payment of EUR 120 million and a one-time reimbursable payment of EUR 30 million for manufacturing capacity reservation, upon certification of CureVac’s commercial scale manufacturing facility currently under construction in Germany. It will also make an equity investment in CureVac of EUR 150 million, representing close to a 10% stake.

"We were delighted to assist CureVac on this important collaboration agreement with GSK to bring together two world-class companies to further develop their potential vaccine and treatment technologies for infectious diseases," said Dr. Constanze Ulmer-Eilfort, lead partner at Baker McKenzie on the transaction.

CureVac is a long-standing client of Baker McKenzie. Under the leadership of Dr. Constanze Ulmer-Eilfort, Baker McKenzie advised CureVac on cooperation agreements with the Bill & Melinda Gates Foundation and CEPI, and most recently on the strategic partnership with Genmab A/S for the development of mRNA-based antibody therapeutics (December 2019).


Legal advisor to CureVac AG:
Baker McKenzie


Lead: IP: Dr. Constanze Ulmer-Eilfort, LL.M. (partner, Munich)

Team: IP: Julia Schieber (senior associate, Zurich), Andreas Jauch (senior associate, Frankfurt)
Antitrust: Dr. Christian Burholt (partner, Berlin)
Pharma: Dr. Thilo Räpple (partner, Frankfurt)
Explore Our Newsroom